Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Taranabant (MK0364) in Overweight and Obese Patients With Type 2 Diabetes Mellitus (T2DM) Followed by a 1-Year Extension

NCT00430742 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT00430742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00430742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Taranabant (MK0364) in Overweight and Obese Patients With Type 2 Diabetes Mellitus (T2DM) Followed by a 1-Year Extension
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 3
Overall status
Terminated
Start date
November 30, 2006
Completion date
November 30, 2008
Enrollment
600 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

obesity type 2 diabetes mellitus, type 2 diabetes mellitus